Warfarin is an anticoagulant commonly used for the management of patients with a variety of thromboembolic conditions
1 but it is implicated in many drug-drug interactions. Some interactions alter warfarin pharmacokinetics and others involve drugs that directly influence hemostasis or gastrointestinal integrity.
2,3 Nonsteroidal anti-inflammatory drugs (NSAIDs) are often coprescribed to patients receiving warfarin, potentially resulting in a significantly increased risk of upper gastrointestinal (GI) hemorrhage.
4 This increased risk may be mediated through several pathways. First, many NSAIDs are substrates for the cytochrome P450 2C9 isoenzyme. Their use may interfere with the oxidative metabolism of S-warfarin, the more active enantiomer of commercially available racemic warfarin, thereby increasing the hypoprothrombinemic response to warfarin.
5 Second, the nonspecific inhibition of cyclooxygenase (COX) enzymes by nonselective NSAIDs leads to significant inhibition of COX-1–generated thromboxane A
2, impairing platelet aggregation,
6,7 which may be further compounded by the concomitant use of warfarin.
8 Third, traditional NSAIDs can cause gastric erosion, thereby further increasing the risk of GI bleeding in patients treated with warfarin.
9